| Comment | 3.660 | Robert Floyd | The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area. | 2007-12-11 | |
| HOLD | 7.310 | Chyanne Fickes | Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent. | 2007-07-05 | |
| SELL | 7.220 | Kenneth P. Norquay, CMT | The whole market is going up, and this one is going down. Let someone else own it. | 2007-06-01 | |
| SELL | 6.290 | Norman Levine | A one trick pony with its coated stent. There is lots of controversy on drug coated stents. | 2007-05-01 | |
| DON'T BUY | 6.850 | Robert Floyd | They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping. | 2007-04-19 | |
| Comment | 6.990 | Chyanne Fickes | Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets. | 2007-04-17 | |
| BUY | 6.170 | John Zechner | The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market. | 2007-04-02 | |
| DON'T BUY | 6.380 | Norman Levine | A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents. | 2007-03-28 | |
| DON'T BUY | 7.200 | Peter Hodson | Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery. | 2007-03-12 | |
| DON'T BUY | 7.200 | Chyanne Fickes | Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down. | 2007-03-12 | |
| DON'T BUY | 7.370 | Brian Acker, CA | If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping. | 2007-03-09 | |
| DON'T BUY | 7.830 | Robert Floyd | Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that. | 2007-02-13 | |
| DON'T BUY | 8.580 | Chyanne Fickes | A great company but not something you should get into at this point. Can't see much upside in the near to intermediate term. Having real problems with clots on their stents. Losing market share. Guidance going forward is coming down. Sold her holdings. | 2007-02-06 | |
| DON'T BUY | 8.580 | Alexander Lane, B Comm, CFA | Have been a lot of concerns on their stent products. As a result of this, they acquired a company that would give them revenue and earnings in the event the stents were pulled. Still a lot of risks. | 2007-02-06 | |
| PAST TOP PICK | 10.810 | John Zechner | (A Top Pick Oct 16/06. Up 9.1%.) Still comfortable with this one. Decent, longer-term story. | 2007-01-22 | |
| BUY | 9.370 | Chyanne Fickes | Got hit with the stent recall for Boston scientific. There are some long-term issues with stents. FDA has decided that the safety issues were not enough to outweigh the benefits. Most of their earnings in the next couple of years will be coming from new products in the pipeline, not stents. Have been very active in acquisitions. | 2006-12-18 | |
| WAIT | 9.820 | Robert Floyd | Have been trying to diversify away from their stent business, which is their major source of revenue. There is a fair amount of competition in the sector. Because of the drop in the share price, it could be subject to some tax loss selling. | 2006-12-01 | |
| TOP PICK | 9.530 | John Zechner | Stock has come down a long way and valuation looks good. Maintaining their share of the coated stent market. That alone could justify the current price. Acquired another company where they can use the coated technology on other products. Lots of cash. Trading at 12 X earnings. | 2006-11-08 | |
| PAST TOP PICK | 9.800 | Chyanne Fickes | (A Top Pick Aug 21/06. Down 19%.) Had some issues with Boston Scientific (BSX-N) and some problems with their stents. Royalty rate is going down. Still likes the company. They are relying less and less on stents. | 2006-11-06 | |
| DON'T BUY | 10.130 | Michael Sprung | Has been under pressure because of competition on their stents. Some controversy as to whether the coated is better or not. Because of this, it is more of a speculation than an investment. | 2006-10-18 | |
| TOP PICK | 9.810 | John Zechner | Has been pummelled in the past year. A bit of a contrarian play. Trading around 11 X forward earnings. Made in acquisition that has a great pipeline and, basically, you are paying nothing for that. The stent market is still growing. | 2006-10-16 | |
| BUY | 9.630 | Chyanne Fickes | Management is great. It is trading at a low price. Believes it is a buy. | 2006-10-02 | |
| TOP PICK | 9.830 | John Zechner | Stock recently hit a 52 week low. He is looking at the turnaround here. It has some growth and a good balance sheet. It is in a sector that he likes. | 2006-09-27 | |
| BUY | 13.350 | Martin Hubbes, CFA | Has come under a bit of pressure which now seems to be easing. Their main business is drug coated stents which they get royalties on. Recently made an acquisition and some of the synergies are now going to start working their way through. | 2006-09-01 | |
| TOP PICK | 13.150 | Chyanne Fickes | Tainted with the stent problem in the US. Incredibly attractive from an earnings point of view. Did some acquisitions that give them 200 new products that they will coat with the same technology they used for their stents. | 2006-08-31 | |
| PAST TOP PICK | 12.850 | David Chapman | (A Top Pick July 4/05. Down 27%.) Below the 50/200-day moving averages. Chart shows a strong downtrend. Had suggested this as a Christmas rally stock. | 2006-08-04 | |
| TOP PICK | 13.540 | John Zechner | Just made a major acquisition. Their coated stent product is still going well. The stock has come under a lot of pressure. They are generating cash and trading at 12 X earnings. | 2006-07-31 | |
| DON'T BUY | 13.230 | Chyanne Fickes | Biotech stocks have not done well for quite awhile. Great company, but the market does not appreciate what they have in their pipeline. Big problem is that all their revenues are from stents via Boston who are having a number of recalls. Made a number of acquisitions in the last few years and expect they will start bearing fruit soon. Good management. | 2006-07-04 | |
| DON'T BUY | 17.010 | David Driscoll | Coming out with other products is going to be their big task down the road. Hit and miss right now. | 2006-04-06 | |
| PAST TOP PICK | 17.500 | David Chapman | (A Top Pick Nov 9/05. Up 4%.) When he picked these stocks, he was trying to play the Christmas bounce. All 3 failed to materialise. This is still in the basing period and has not broken out yet. | 2006-03-28 | |
| DON'T BUY | 18.100 | Gavin Graham | Manufactures coated stents. In competition with Johnson & Johnson (JNJ-N). A one trick pony. Boston Scientific (BSX-N) is a better way to play this. | 2006-03-20 | |
| VAGUE | 17.450 | Bill Carrigan | He believes the sector is good, but has no position on this stock. | 2006-02-14 | |
| WATCH | 17.450 | Norman Levine | Just acquired American Medical Instruments. This is a very positive move which gives them the ability to grow. They'll have to do more of this to get the stock moving. | 2006-02-13 | |
| DON'T BUY | 16.550 | Norman Levine | Boston Scientific (BSX-N) is buying Guidant (GDT-N) which is a competitor of Angiotech. This is very negative for Angiotech. This company has been a one-hit wonder. | 2005-12-05 | |
| TOP PICK | 16.780 | David Chapman | (A Top Pick July 4/05. Down 5%.) It is hard trying to read companies in the health care sector, but this one has had a long base with a lot of series of lows which seems to be that it is getting ready for a pop. All his picks are for a seasonal Santa Claus rally trade. If they move 20%, say thank you and get the heck out. | 2005-11-09 | |
| BUY | 15.870 | John Zechner | Trading at around 13 X earnings which is cheap for a company that is growing. Market has given them a lot of credit for their coated stent, but is worried about competion and with them owning 75% of the market are not sure they can hold this. At a very cheap level now. Has bought it, and will continue to hold. | 2005-09-29 | |
| DON'T BUY | 15.320 | Larry Berman CFA, CMT, CTA | Using a 5 year chart as he wants to look at as it is coming back to multi-year support level. The trend is still bearish and there is no sign of it ending. Getting close to long term support and from that perspective it gets interesting. You need to see positive price action and some volume coming in. | 2005-09-28 | |
| BUY | 16.230 | David Baskin | Angiotech and Boston Scientific (BSX-N) are up against Johnson & Johnson (JNJ-N) which is like being in the ring with a heavyweight. Lost ground when they had their product recalled. Still a good company. | 2005-09-19 | |
| DON'T BUY | 15.970 | David Burrows | The medical device group is performing fairly well. The problem this company is having is that it is really a one product company which is a risk. Competition Johnson and Johnson (JNJ-N) has a product which is perceived to be safer so market share has dropped. | 2005-08-25 | |
| WEAK BUY | 15.750 | Jim Huang | Had some rough patches lately. Biggest claim to fame is licensing of their technology to Boston Scientific. They continue to be successful, the problem is, what do they do for an encore. Sales are set to decline. Have a good cash position and hopefully they will come up with a new product that will be successful. High risk and potentially high reward. | 2005-08-22 | |
| BUY | 16.580 | Gavin Graham | Continues to like this stock. Their stents, sold through Boston Scientific (BSX-N) is gaining market share over Johnson & Johnson (JNJ-N). A world class Canadian winner. | 2005-08-08 | |
| TOP PICK | 17.680 | David Chapman | The biotech sector of the TSX is absolutely the worst sector of the past couple of years. This one is a highly speculative pick. Can see a descending wedge on the chart which is a bullish sign. Watch for the breakout to the upside. | 2005-07-04 | |
| DON'T BUY | 17.290 | Fred Sturm | Comes into the health care theme that he thinks will be dominate into the next 10 years. Not his favourite way to participate. | 2005-06-22 | |
| DON'T BUY | 17.640 | Danny Tomka | Boston Scientific (BSX-N) had the majority share in the business, they are a supplier, so why is it weak. Boston is just as weak. The problem with the pharma sector is investors never look at what it is today but what is the marginal change tomorrow, such as competition with a better product. | 2005-03-29 | |
| VAGUE | 18.720 | Kevin Vandermeer, B.Comm, CFA | Technology is superior then Boston Scientific, and Boston markets for them. (for their main product). Would rather buy Boston, because it is more diversified, and slightly cheaper. | 2005-03-11 | |
| BUY | 21.950 | John Zechner | Longer term, they're going to have to start filling their pipeline more. Coated stents have been a great success. Distributor, Boston Scientific, have about 70% of the market so far which will generate great cash over the next couple of years. Management is good and should be able to redeploy cash to build up by acquisitions, etc. | 2005-02-14 | |
| VAGUE | 22.990 | Gavin Graham | The coating on the stents seems to be a bit better than the ones from Johnson & Johnson. | 2005-02-07 | |
| DON'T BUY | 22.990 | Brian Acker, CA | Fully valued. | 2005-02-07 | |
| WAIT | 22.990 | Larry Berman CFA, CMT, CTA | His technical screening looks for stocks that are forming base patterns. Starting to see that now and starting to get a little bit attractive. Hasn't done anything positive in terms of upside volume, surges or money flow. Once you see that, the story gets really exciting. | 2005-02-07 | |
| BUY | 22.390 | David Baskin | As an emerging technology, the stock got a very high multiple, but once it gets up there, how do you keep that high multiple? Very difficult unless you continue to have new products and excitement. A solid company with a solid product, but doesn't think it will ever get the multiple that it had before. Probably an OK buy today. | 2004-12-16 | |
| DON'T BUY | 23.510 | Ron Meisels | Had a major sell off and is probably in some what of a support zone. Still below its 200 day moving average. | 2004-11-16 | |
| PAST TOP PICK | 24.360 | John Zechner | (A Top Pick June 23/04. Down 15%.) Had a recall of their stent 2 days later and they dropped market share to 55%, but are now back to 70%. Still buying. | 2004-11-11 | |
| BUY | 24.530 | Martin Hubbes, CFA | A good probability that the stock will move higher. Everything is lining up for them to get a higher royalty from Boston Scientific. | 2004-11-05 | |
| PAST TOP PICK | 22.330 | Michael Sprung | (A Top Pick Aug 17/04. Up 11%.) Their distributor, Boston Scientific, have announced very good results. Market share is back to where it was before the stent recall. Looking to expand their technology in stents. | 2004-10-21 | |
| HOLD | 22.280 | Robert Floyd | Bullish on this company. Revenue stream from their coated stents is looking quite strong. | 2004-10-19 | |
| DON'T BUY | 25.560 | Gordon Higgins, CA, MBA, CFA | A very volatile stock. A one product stock. | 2004-09-30 | |
| BUY | 24.450 | Peter Brieger | Looking at it. Likes the stock. Long term buy. | 2004-09-29 | |
| TOP PICK | 24.200 | Michael Sprung | Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart. | 2004-09-28 | |
| DON'T BUY | 22.250 | Norman Levine | There should be some recovery and show that they have good products coming out. Do not rush to own the stocks. | 2004-08-27 | |
| DON'T BUY | 22.620 | Ron Meisels | To tell when a stock has bottomed, you need to see more trading at the low level indicating that the sell off is over. Stock is on a negative trend. | 2004-08-24 | |
| BUY | 22.390 | Robert Floyd | Had some troubles along with Boston Scientific with stent recalls. FDA is allowing them to keep stents three months longer which created a bit of a rally. Reasonable value at this price. | 2004-08-23 | |
| TOP PICK | 20.050 | Michael Sprung | Feels they handled their recent problems extremely well. Have quite a good product mix going forward. | 2004-08-17 | |
| DON'T BUY | 20.550 | Michael Smedley | A difficult one. A clever Company and an important one. Very deeply based on the stent business. | 2004-08-12 | |
| WAIT | 22.440 | John Sinkins, CFA | Got knocked down because of a short term recall on Boston Scientific stents. A short-term problem. Wait and see. | 2004-07-28 | |
| DON'T BUY | 21.250 | Gordon Higgins, CA, MBA, CFA | Boston Scientific just did a recall on 85,000 stents. Nothing wrong with the Angiotech product, but their partner is having a problem, so at this point it's a gamble. | 2004-07-23 | |
| VAGUE | 21.800 | Norman Levine | The market has been hurting them because they have not branched out into other areas. The recall of Boston Scientific's stent has also hurt. | 2004-07-19 | |
| BUY | 23.600 | Ron Meisels | Built a big base from 2000 into 2003 and then took off but at $40 the stock started to weaken. In the minor downtrend. Support will probably come at the $22/23 so you could start buying. | 2004-07-14 | |
| DON'T BUY | 26.550 | Jonathen Wellum, B. Comm, B. Sc | Prefers businesses with as much visibility as possible so they can get their minds around. Has done an amazing job. Brutally competitive market. Prefers companies with more diversification. | 2004-06-25 | |
| TOP PICK | 27.960 | John Zechner | Price has dropped and looks at this as an opportunity. Competition is not strong. Lots of cash. Well-positioned. | 2004-06-23 | |
| VAGUE | 27.960 | John Weatherall | The big question is, Will their stent covering continue to hold a major share of the market. | 2004-06-23 | |
| DON'T BUY | 26.940 | Norman Levine | Having Boston Scientific involved and Johnson and Johnson having problems with their stent, is already priced into the stock. | 2004-06-18 | |
| HOLD | 27.820 | Michael Smedley | Doesnt know if it's a good point of entry. A single product company. Story is well known. | 2004-06-16 | |
| TOP PICK | 28.090 | John Zechner | Surprised that it hasn't moved a little more recently. Should do very well on the royalties in the coated stent market. Trades at 15 X next year's earnings. Building a pipeline as well. | 2004-06-10 | |
| WAIT | 28.300 | David Burrows | Has had a pretty good pullback in the last little while. Their marketer, Boston Scientific, on the other hand has been doing very well. Earnings/revenue are coming in much better than expected but wait for a positive trend to be established. | 2004-06-07 | |
| TOP PICK | 30.100 | Andrew McCreath | Coated stents is probably the biggest area in the medical arena. Have reported good data. Expects their royalty rates to go up this summer. | 2004-05-31 | |
| WAIT | 30.000 | David Burrows | Stents have shown dramatic improvements. Not in a hurry to add money to the sector they are in. A good indicator is to watch Boston Scientific in the US who is marketing their stents. If it goes to a new high, that would be the time to get in. | 2004-05-27 | |
| HOLD | 25.900 | Norman Levine | Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich. | 2004-05-17 | |
| BUY | 27.600 | John Zechner | With Boston Scientific handling sales, you should see a growth. A great story. | 2004-05-06 | |
| DON'T BUY | 27.570 | Brian Acker, CA | Was a great stock as a concept stock but when manufacturing starts, the stock falls apart. Model price of $22. | 2004-04-28 | |
| BUY | 28.500 | Gavin Graham | Down a little bit, but still should make lots of money. | 2004-04-27 | |
| TOP PICK | 31.200 | John Zechner | The numbers four Boston Scientific have been spectacular. They have a better delivery stent. Should have a 70% market share. | 2004-04-22 | |
| TOP PICK | 32.240 | Andrew McCreath | Coated stents have done very well. Boston Scientific just reported that the stents captured 70% of the market and had $98 million in sales. Accelerating momentum. We'll probably earn $.80/.90 this year and double next year. | 2004-04-20 | |
| BUY | 32.240 | Ian Ainsworth | A great company and one of Canada's success stories in biotech's. Prefers playing this through Boston Scientific which has better valuation. | 2004-04-20 | |
| BUY | 32.810 | David Baskin | A great product. Tremendously high margins. Should make some money. Growth will be slower than what it has been in the past. | 2004-04-13 | |
| DON'T BUY | 32.810 | Mark Jackson, CFA | Has been a great stock but doesn't think there's any more news for it. Fully valued. | 2004-04-13 | |
| DON'T BUY | 30.850 | David Baskin | Has a problem with intellectual properties in biotech companies and competition, which in their case is Johnson and Johnson. | 2004-03-24 | |
| BUY | 32.810 | Ron Meisels | Had a good base and broke out in early 2003. It must not break down through $30, but otherwise a good stock. Stop loss of $27/28. | 2004-03-17 | |
| VAGUE | 32.090 | Norman Levine | At the same time there stent was approved, Johnson & Johnson went partners with partners with Guidance. Long-term, this stock and their partner Boston Scientific will be very good. | 2004-03-12 | |
| BUY | 33.400 | Gavin Graham | Approval has been given for Boston Scientific to sell its drug-coated stent. A safe way to play the stent market. Also have a relationship with Guidant which expects to put a stent in the market. | 2004-03-04 | |
| BUY | 33.600 | David Burrows | Down today, but things it's a short term blip. Isn't taking it out of its trend. There is a risk that their stent will not be approved but feels it is a small risk. | 2004-02-24 | |
| BUY | 36.950 | Vincent Delisle | Still sees some upside in the long-term. Fundamentals are good. | 2004-02-16 | |
| HOLD | 38.000 | Norman Levine | Riding the waves of Boston Scientific. Keep riding it. | 2004-02-11 | |
| BUY | 38.170 | Michael Sprung | Like. Nice place in market. They earn money. They're one of the best in the fierl. Positive outlook | 2004-02-09 | |
| VAGUE | 35.820 | Ron Meisels | Moving average is rising. Just had a breakout. Best time to jump in is when stock hits all time high. | 2004-02-02 | |
| HOLD | 34.640 | Brian Acker, CA | Very expensive. Earnings aren't there yet. They have to sell their products. Stock market price is on potential. The potential is there, so hang on. | 2004-01-30 | |
| BUY | 65.890 | David Baskin | Have done wonderfully. A stock split is due in February. Demand for their product is very strong. Not cheap. Management has done really well. | 2004-01-22 | |
| WEAK BUY | 59.580 | Peter Arender, CFA | Has a volatiltiy of earnings, trading higher than it should. | 2003-12-23 | |
| BUY | 61.750 | Gavin Graham | A world-class company. The drugs that cover the stents has just been approved by the FDA. A great leverage play on Boston Scientific getting a big part of the stent market. | 2003-12-15 | |
| DON'T BUY | 66.090 | Vincent Delisle | A lot of its good news is priced into the stock right now. | 2003-12-02 | |
| BUY | 62.150 | Mike Weir | Now crossing into profitability. When their stent hits the US market, the earnings will drive a lot higher. | 2003-11-25 | |
Experts that have talked about Angiotech Pharmaceuticals
Rss Top Picks Feed
